Compare AstraZeneca plc (AZN) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Williams-Sonoma, Inc. — how do they compare? AstraZeneca plc trades at $158.57 (market cap $248.14B), while Williams-Sonoma, Inc. trades at $246.32 (market cap $29.51B). The key difference: AstraZeneca plc is far larger — about 8.4× Williams-Sonoma, Inc.'s market cap, and AstraZeneca plc pays the higher dividend (2.01%). Which is the better fit depends on your goals.
| AZN | WSM | |
|---|---|---|
Market Cap | $248.14B | $29.51B |
Sector | Health | Consumer Cyclical |
52-Week High | $209.48 | $251.81 |
52-Week Low | $147.06 | $168.64 |
Enterprise Value | $275.41B | $30.35B |
Dividend Yield | 2.01% | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
Williams-Sonoma (WSM) trades at $246.14, down 1.87% on the day, amid a generally bullish technical outlook. The stock shows strong profitability with a net income margin of 13.81% and has beaten earnings estimates for three consecutive quarters. Recent news highlights its digital-first transformation and competitive strength in home furnishings.
The outlook is supported by solid fundamentals and positive earnings momentum, but high valuation ratios and overbought RSI levels pose near-term risks. Analyst consensus is mixed, with a moderate buy rating but a price target below the current price, suggesting cautious optimism amid execution and consumer spending concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
